| Identification | Back Directory | [Name]
N-(3-bromobenzoyl)-N'-(2-methylphenyl)thiourea | [CAS]
364621-46-5 | [Synonyms]
TFCP2L1-IN-1
N-(3-bromobenzoyl)-N'-(2-methylphenyl)thiourea
3-bromo-N-[(2-methylphenyl)carbamothioyl]benzamide
Benzamide, 3-bromo-N-[[(2-methylphenyl)amino]thioxomethyl]- | [Molecular Formula]
C15H13BrN2OS | [MOL File]
364621-46-5.mol | [Molecular Weight]
349.25 |
| Hazard Information | Back Directory | [Uses]
TFCP2L1-IN-1 is a specific small molecule targeting TFCP2L1’s active domain with anti-cancer activity. TFCP2L1-IN-1 synergizes with Sorafenib (HY-10201) to induce Apoptosis and reduces cell proliferation, invasion, metastasis, clonal formation and sphere-forming capacity in hepatocellular carcinoma cells[1]. | [References]
[1] Qiu D, et al. TFCP2L1 drives stemness and enhances their resistance to Sorafenib treatment by modulating the NANOG/STAT3 pathway in hepatocellular carcinoma. Oncogenesis. 2024 Sep 12;13(1):33. DOI:10.1038/s41389-024-00534-1 |
|
| Company Name: |
Specs
|
| Tel: |
+31 15 251 8111 |
| Website: |
www.specs.net |
|